An-Jing Ren

Overexpression of microRNA-378 attenuates ischemia-induced apoptosis by inhibiting caspase-3 expression in cardiac myocytes

MicroRNAs (miRNAs) are a novel class of powerful, endogenous regulators of gene expression. In an intact rat model of myocardial ischemia caused by coronary artery ligation, this study identified 17 miRNAs that changed more than 1.5-fold in the myocardium subjected to 4-h ischemia. Using miRNA microarray analysis, most of these aberrantly expressed miRNAs were confirmed by quantitative RT-PCR. MiR-378, a significantly down-regulated miRNA, was selected for further function study. In serum deprived rat H9c2 cardiomyocytes exposed to hypoxia (1% O2), miR-378 expression was down-regulated as well. The overexpression of miR-378 resulting from miR-378 mimic transfection significantly enhanced cell viability, reduced lactate dehydrogenase release, and inhibited apoptosis and necrosis. By contrast, miR-378 deficiency resulting from miR-378 inhibitor transfection aggravated the hypoxia-induced apoptosis and cell injury. In accordance, miR-378 inhibitor caused significant apoptosis and cell injury to cardiomyocytes cultured under normoxia. Using bioinformatic algorithms, caspase-3, a key apoptosis executioner, was predicted as a putative target of miR-378. The quantitative RT-PCR showed no effects of miR-378 mimic or inhibitor on caspase-3 mRNA level. However, the amount of caspase-3 proteins was reduced by miR-378 mimic, whereas increased by miR-378 inhibitor. Furthermore, the luciferase reporter assay confirmed caspase-3 to be a target of miR-378, and the apoptosis and cell injury caused by miR-378 inhibitor in both normoxic and hypoxic cells were abolished by a caspase-3 inhibitor. This study first showed that miR-378 inhibited caspase-3 expression and attenuated ischemic injury in cardiomyocytes. It may represent a potential novel treatment for apoptosis and ischemic heart disease.

MicroRNAs are dynamically regulated in hypertrophic hearts, and miR-199a is essential for the maintenance of cell size in cardiomyocytes†

Cardiac hypertrophy, which is characterized by an increase in cell size and reactivation of fetal genes, occurs as an adaptive response to diverse forms of stress and often results in heart failure and sudden death. Growing evidence indicates that microRNAs (miRNAs) are involved in cardiac hypertrophy, but the function of these miRNAs remains elusive. Here, using real time PCR analysis, we showed that several miRNAs were dynamically regulated in the rat hypertrophic hearts and miR‐199a was up‐regulated by 10‐fold in hypertrophic hearts after abdominal aorta constriction for 12 weeks. With tissue profiling analysis, we showed that miR‐199a was predominantly expressed in cardiomyocytes, but was also faintly detected in cardiac fibroblasts. To investigate whether miR‐199a was involved in cardiac hypertrophy, both over‐expression and knockdown of miR‐199a were performed in cultured cardiomyocytes. Over‐expression of miR‐199a in cardiomyocytes increased the cell size as measured by cell surface area, and also reduced the mRNA expression level of α‐myosin heavy chain. In accordance, knockdown of endogenous miR‐199a in cardiomyocytes reduced the cell size. Down‐regulation of miR‐199a also attenuated the phenylephrine‐induced increase of cell size. Furthermore, bioinformatic algorithms were used to predict the potential targets of miR‐199a in cardiac hypertrophy, and hypoxia‐inducible factor 1 alpha was confirmed by the luciferase reporter assay to be a potential target of miR‐199a. Taken together, our results demonstrated that miR‐199a, which was predominantly expressed in cardiomyocytes, was essential for the maintenance of cell size of cardiomyocytes and might play a role in the regulation of cardiac hypertrophy. J. Cell. Physiol. 225: 437–443, 2010.

Inhibitory effect of obestatin on glucose-induced insulin secretion in rats.

Obestatin is a bioactive peptide encoded by the same gene that encodes ghrelin. Our aim was to investigate the effect of obestatin on insulin secretion. We evaluated the effects of obestatin on insulin secretion from rat islet cells which had been incubated overnight in the presence of 8.3, 11.1, and 22.2 mmol/l of glucose. In vivo, the serum levels of glucose and insulin were measured 0, 1, 5, 10, 20, 40, and 60 min after the intravenous administration of saline or glucose (1g/kg), with or without obestatin, and the area under the 60 min curve of insulin concentration (AUC(insulin)) was calculated. Obestatin (0.01-100 nmol/l) inhibited insulin secretion from rat islets in a dose-dependent fashion. In vivo, when administered intravenously to rats together with glucose, obestatin (10, 50, and 250 nmol/kg) inhibited both the rapid 1-min insulin response and the AUC(insulin) in a dose-dependent fashion. Our data demonstrate that under glucose-stimulated conditions, exogenous obestatin acts as a potent inhibitor of insulin secretion in anaesthetized rats in vivo as well as in cultured islets in vitro.

Different responses of circulating ghrelin, obestatin levels to fasting, re-feeding and different food compositions, and their local expressions in rats

Obestatin, a sibling of ghrelin derived from preproghrelin, opposes several physiological actions of ghrelin. Our previous study has demonstrated that both plasma ghrelin and obestatin levels were decreased significantly 2h after food intake in human. To further expand current knowledge, we investigated the temporal profiles of their levels in ad libitum fed rats, 48h fasted rats and 48h fasted rats refed 2h with a standard chow, crude fiber, 50% glucose or water, and their expressions in stomach, liver and pancreatic islets immunohistochemically. Plasma ghrelin and obestatin levels were measured by EIA. Plasma leptin, insulin and glucose levels were also evaluated. Both plasma ghrelin and obestatin levels increased significantly in fasted rats compared with ad libitum fed rats. The ingestion of standard chow produced a profound and sustained suppression of ghrelin levels, whereas plasma obestatin levels decreased significantly but recovered quickly. Intake of crude fiber or 50% glucose, however, produced a more profound and sustained suppression of obestatin levels, though they had relatively less impact on ghrelin levels. Plasma glucose was the only independent predictor of ghrelin levels, obestatin levels, and ghrelin to obestatin ratios. Obestatin immunoreactivity was detected in the fundus of stomach, liver and pancreatic islets, with roughly similar patterns of distribution to ghrelin. These data show quantitative and qualitative differences in circulating ghrelin and obestatin responses to the short-term feeding status and nutrient composition, and may support a role for obestatin in regulating metabolism and energy homeostasis.

HSP70 and GRP78 induced by endothelin-1 pretreatment enhance tolerance to hypoxia in cultured neonatal rat cardiomyocytes.

The heat shock protein 70 and glucose-regulated protein 78 have been shown to protect cells against deleterious stimuli. This study was performed to determine whether endothelin-1 pretreatment could increase cardiomyocyte tolerance to hypoxia and induce heat shock protein 70 and glucose-regulated protein 78 expression. Cultured cardiomyocytes were treated with endothelin-1 at doses of 0.01, 0.1 and 1.0 nmol/L for 10 minutes followed by 10 minutes endothelin-1-free normal medium prior to 12 hours hypoxia. Lactate dehydrogenase activity and malondialdehyde level in the medium were determined at the end of hypoxia, and myocyte heat shock protein 70 and glucose-regulated protein 78 were assayed with Western blot. Lactate dehydrogenase activity and malondialdehyde content in the medium were significantly elevated after hypoxia (P < 0.01, n = 6). Heat shock protein 70 and glucoseregulated protein 78 expression in cardiomyocytes also increased significantly after hypoxia (P < 0.01 vs control, n = 3). Endothelin- 1 pretreatment reduced lactate dehydrogenase and malondialdehyde after hypoxia, and increased heat shock protein 70 and glucoseregulated protein 78 levels during normal culture and hypoxia. Glucose-regulated protein 78 antisense oligodeoxynucleotide partially abrogated the protective effect of endothelin-1 pretreatment on hypoxic cardiomyocyte injury. This study indicated that endothelin-1 pretreatment could protect hypoxic cardiomyocytes and might exert this effect through upregulation of heat shock protein 70 and glucose-regulated protein 78.

Obestatin, obesity and diabetes

The high prevalence of obesity and diabetes will lead to higher rates of morbidity and mortality. It is well known that ghrelin plays a potential role in obesity and diabetes. Obestatin, a novel 23 amino acid amidated peptide encoded by the same gene that encodes ghrelin, was initially reported to have opposite actions to ghrelin in the regulation of food intake, emptying of the stomach and body weight. Recent work suggests that obestatin also regulate beta-cell survival and insulin secretion. The ghrelin-obestatin system is, therefore, a promising target for the developing of new drugs for the treatment of obesity and diabetes. This review summarizes the interrelationship between obestatin, obesity and diabetes.

Disturbance of circulating ghrelin and obestatin in chronic heart failure patients especially in those with cachexia

Plasma ghrelin was elevated in chronic heart failure (CHF) patients with cachexia. Obestatin, a sibling of ghrelin, opposes several actions of ghrelin. We, therefore, investigated plasma obestatin and ghrelin levels in patients with CHF. Total plasma ghrelin and obestatin levels were measured in 65 patients with CHF (22 with cardiac cachexia) and 15 controls. Ghrelin levels were significantly higher in patients with cachexia (1237.8+/-47.9 pg/ml) than those without cachexia (P=0.041) and controls (P<0.01). Obestatin levels correlated positively with ghrelin levels, and obestatin levels were significantly increased in patients with cachexia (282.3+/-13.0 pg/ml) than patients without cachexia and controls (both P<0.01). However, the ghrelin to obestatin ratios (4.5+/-0.2) were significantly lower in CHF patients with cachexia than controls (P<0.01). Ghrelin and ratio of ghrelin to obestatin were independent predictors of the development of cardiac cachexia. No association was found between ghrelin, obestatin and New York Heart Association functional class, brain natriuretic peptide. There was disturbance of circulating ghrelin and obestatin in the CHF patients especially those with cachexia, which may have a role in the pathogenesis of cardiac cachexia in CHF.

Leptin protects cardiomyocytes from serum-deprivation-induced apoptosis by increasing anti-oxidant defence.

1. Leptin, an important adipose‐derived hormone, can be associated with cardiac pathophysiology; however, the role of leptin in cardiomyocyte apoptosis is poorly understood. The present study examines serum‐deprivation‐induced apoptosis in primary cultured cardiomyocytes treated with leptin.

Association of obestatin with blood pressure in the third trimesters of pregnancy

Obestatin is a recently discovered 23-amino acid peptide encoded by the same gene that encodes ghrelin. It has been reported that there is a significant negative correlation between the plasma ghrelin concentration and systemic blood pressure in patients with pregnancy-induced hypertension. We investigated the plasma concentration of obestatin in 18 non-pregnant women, 18 normal pregnant women, and 15 patients with pregnancy-induced hypertension. The plasma concentrations of obestatin in these 3 groups of women were 63.4+/-9.5pg/ml, 38.1+/-6.3pg/ml, and 46.0+/-9.3pg/ml, respectively. In non-pregnant women, there was no correlation between the plasma obestatin concentration and the mean arterial pressure. However, there was a positive correlation between the plasma obestatin concentration and the mean arterial pressure in normal pregnant women and pregnant women with pregnancy-induced hypertension. These results suggest that obestatin may have some potential role in the regulation of blood pressure in normal pregnant women and women with pregnancy-induced hypertension.

Bolus intravenous injection of obestatin does not change blood pressure level of spontaneously hypertensive rat

Ghrelin, an endogenous ligand for the GH secretagogue receptor, has been shown to decrease arterial pressure. Obestatin, a sibling of ghrelin derived from preproghrelin, opposes several physiological actions of ghrelin. The aim of this study was to determine the effects of bolus intravenous injection of obestatin on blood pressure in spontaneously hypertensive rats. Three different dosages of obestatin (10, 50, and 100 microg/kg) and one dosage of ghrelin (10 microg/kg) were applied. The mean arterial pressure and heart period were continuously recorded for 30 min after injection of drugs. Baroreflex sensitivity was also investigated. In this study, we first demonstrated that intravenous injection of obestatin showed no significant effects on mean blood pressure (10 microg/kg: 113.8+/-2.0 mmHg vs. 114.4+/-1.6 mmHg; 50 microg/kg: 110+/-2.4 mmHg vs. 109+/-3.2 mmHg; 100 microg/kg: 115.9+/-1.5 mmHg vs. 115.8+/-2.4 mmHg; all P>0.05), heart period (10 microg/kg: 184.7+/-3.9 ms vs. 185.5+/-4.1ms; 50 microg/kg: 185.9+/-4.1 ms vs. 193.4+/-4.5 ms; 100 microg/kg: 137.7+/-4.5 ms vs. 143.9+/-5.6 ms; all P>0.05), or baroreflex sensitivity (10 microg/kg: 0.414+/-0.03 ms/mmHg vs. 0.442+/-0.02 ms/mmHg; 50 microg/kg: 0.453+/-0.04 ms/mmHg vs. 0.439+/-0.01 ms/mmHg; 100 microg/kg: 0.398+/-0.02 ms/mmHg vs. 0.401+/-0.01 ms/mmHg; all P>0.05), however, intravenous injection of ghrelin could decrease mean arterial pressure (115.9+/-1.5 mmHg vs. 108.6+/-3.6 mmHg, P<0.01) and increase heart period (132.4+/-2.8 ms vs. 152.6+/-7.4 ms, P<0.05), but did not change baroreflex sensitivity (0.36+/-0.009 ms/mmHg, P>0.05) in spontaneously hypertensive rats.